RxDoctor Payments Data

Mary Burgeson, MD

Family Medicine · Huntingburg, INNPI 1972565026

Payments from drug & device makers

$8,523in general payments, 2019–2025

Across 607 payments — averaging $14.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Lilly USA, LLC$748
  • Pfizer$591
  • AstraZeneca$552
  • GSK$474
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,29397%
  • Education$2303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,523 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$150,954
Medicare patients
422
Services billed
1,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban202$115,313
JardianceEmpagliflozin105$82,385
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$43,106
JanuviaSitagliptin Phosphate59$37,567
MyrbetriqMirabegron57$36,780
MounjaroTirzepatide35$36,355
ShingrixVaricella-Zoster Ge/As01b/Pf152$31,640
OzempicSemaglutide31$30,890
ArexvyRsvpref3 Antigen/As01e/Pf93$27,495
KerendiaFinerenone25$23,127
VraylarCariprazine Hcl12$15,992
LinzessLinaclotide27$14,795
XareltoRivaroxaban17$14,765
Nurtec OdtRimegepant Sulfate13$12,778
RybelsusSemaglutide13$12,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$591$128,091215 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$474$102,242309 claims
Boehringer IngelheimJardiance$223$82,385105 claims
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$748$51,39084 claims
Novo NordiskOzempic, Rybelsus$1,032$43,27944 claims
MerckJanuvia, Dulera$206$41,71971 claims
Astellas Pharma US IncMyrbetriq$304$36,78057 claims
AbbVieVraylar, Linzess$1,014$30,78739 claims
BayerKerendia$262$23,12725 claims
Johnson & JohnsonXarelto$281$14,76517 claims
AstraZenecaFarxiga$552$9,90847 claims
Sumitomo Pharma America, Inc.Gemtesa$42$3,03812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Huntingburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →